To determine the safety of stem cell harvesting after administration of filgrastim ( G-CSF )
to mobilize bone marrow stem cells into the peripheral blood in patients at various stages of
HIV-1 infection as well as in HIV-negative volunteers. To determine the surface phenotypic
and functional characteristics as well as the viral load in the stem cells obtained following
this procedure.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)